Abstract:Background: Long QT syndrome 3 (LQT3) is caused by SCN5A mutations. Late sodium current (late INa) inhibitors are current-specific to treat patients with LQT3, but the mechanisms underlying mexiletine (MEX) -sensitive (N1325S and R1623Q) and -insensitive (M1652R) mutations remains to be elucidated.Methods: LQT3 patients with causative mutations were treated with oral MEX following i.v. lidocaine. Whole-cell patch-clamp techniques and molecular remodeling were used to determine the mechanisms underlying the sensitivity to MEX.Results: Intravenous administration of lidocaine followed by MEX orally in LQT patients with N1325S and R1623Q sodium channel mutation shortened QTc interval, abolished arrhythmias, and completely normalized the ECG. In HEK293 cells, the steady-state inactivation curves of the M1652R channels were rightward shifted by 5.6 mV relative to the WT channel. In contrast, the R1623Q mutation caused a leftward shift of the steady-state inactivation curve by 15.2 mV compared with WT channel, and N1325S mutation did not affect steady-state inactivation (n = 5–13, P < 0.05). The extent of the window current was expanded in all three mutant channels compared with WT. All three mutations increased late INa with the greatest amplitude in the M1652R channel (n = 9–15, P < 0.05). MEX caused a hyperpolarizing shift of the steady-state inactivation and delayed the recovery of all three mutant channels. Furthermore, it suppressed late INa in N1325S and R1623Q to a greater extent compared to that of M1652R mutant channel. Mutations altered the sensitivity of Nav1.5 to MEX through allosteric mechanisms by changing the conformation of Nav1.5 to become more or less favorable for MEX binding. Late INa inhibitors suppressed late INa in N1325S and R1623Q to a greater extent than that in the M1652R mutation (n = 4–7, P < 0.05).Conclusion: The N1325S, R1623Q, and M1652R mutations are associated with a variable augmentation of late INa, which was reversed by MEX. M1652R mutation changes the conformation of Nav1.5 that disrupt the inactivation of channel affecting MEX binding, corresponding to the poor response to MEX. The lidocaine test, molecular modeling, and drugs screening in cells expressing mutant channels are useful for predicting the effectiveness of late INa inhibitors.

Binding characteristics of calpastatin domain L to NaV1.5 sodium channel and its IQ motif mutants

Properties of Calmodulin Binding to NaV1.2 IQ Motif and Its Autism-Associated Mutation R1902C

Mutations In Cytoplasmic Loops Of The Kcnq1 Channel And The Risk Of Life-Threatening Events Implications For Mutation-Specific Response To Beta-Blocker Therapy In Type 1 Long-Qt Syndrome

Structure of human Na<sub>v</sub>1.5 reveals the fast inactivation-related segments as a mutational hotspot for the long QT syndrome

Α-1-syntrophin Mutation and the Long-QT Syndrome

Reduction in Cardiac Kir3.4 Channel Expression Causes Congenital Long QT Syndrome: A Functional Role of Girk Currents in Ventricular Repolarization

Computational Analysis of the Effects of KCNJ2-linked E299V Mutation Short QT Syndrome and Its Potential Therapeutic Targets

Gating Properties of Mutant Sodium Channels and Responses to Sodium Current Inhibitors Predict Mexiletine-Sensitive Mutations of Long QT Syndrome 3

A Weak Dominant Negative Mutation of KCNQ1-G269S Affects PKA-Mediated Up-Regulation of IKs Channels and Causes Adrenergic Triggered Long QT Syndrome

Alterations of Nedd4-2-binding Capacity in PY-motif of NaV 1.5 Channel Underlie Long QT Syndrome and Brugada Syndrome.

Pharmacological Activation of Normal and Arrhythmia-Associated Mutant KCNQ1 Potassium Channels

Electrophysiological Characteristics Of A Scn5a Voltage Sensors Mutation R1629q Associated With Brugada Syndrome

Novel Gain-of-Function Mutation in the Kv11.1 Channel Found in the Patient with Brugada Syndrome and Mild QTc Shortening

Comparative structural analysis of human Na<sub>v</sub>1.1 and Na<sub>v</sub>1.5 reveals mutational hotspots for sodium channelopathies

Calmodulin binds to the N-terminal domain of the cardiac sodium channel Nav1.5

Mechanistic insights into the interaction of cardiac sodium channel Nav1.5 with MOG1 and a new molecular mechanism for Brugada syndrome

A Novel Cardiac Nav1.5 Channel Mutation, L812Q, Leads to Brugada Syndrome

A mutation causing Brugada syndrome identifies a mechanism for altered autonomic and oxidant regulation of cardiac sodium currents

Structure of Human Na V 1.5 Reveals the Fast Inactivation-Related Segments As a Mutational Hotspot for the Long QT Syndrome

Functional regulation of Kv4.3 by 157T and V65M, two kinds of LQT6 associated mutations in KCNE2

Accelerated inactivation in a mutant Na(+) channel associated with idiopathic ventricular fibrillation.